Pfizer Abrysvo by Pfizer Inc. - RSV vaccine targets older adults and pregnancy

Pfizer Abrysvo is the kind of product you picture when a nurse rolls a silver tray into a bright outpatient room, the syringe catching the overhead light. It is Pfizer’s respiratory syncytial virus (RSV) vaccine for older adults and pregnant women, and Anja in regulatory affairs at Pfizer Germany says she still remembers the first safety briefing because “everyone knew RSV was the missing piece alongside flu and COVID”.

Two indications, one vaccine

Abrysvo is a bivalent RSV prefusion F protein vaccine, designed to protect against both RSV-A and RSV-B, the two main RSV subgroups that drive severe respiratory infections in adults and infants. It is supplied as a single-dose vial that needs to be reconstituted before injection, with the final dose given as a 0.5 ml intramuscular shot. On the CDC’s product pages, Abrysvo is described as a non-live vaccine, meaning it does not contain live virus and is instead based on a stabilized RSV F protein in its prefusion conformation.

The core positioning of Abrysvo is double: it is authorized for adults 60 years of age and older, and for use during pregnancy to protect infants through maternal antibody transfer. The US Food and Drug Administration (FDA) first approved the vaccine for adults 60+ in May 2023, then extended the indication in August 2023 to include pregnant individuals between 32 and 36 weeks of gestation to help reduce RSV-related illness in newborns. In the European Union, the European Medicines Agency (EMA) followed with a positive opinion and subsequent approval for both older adults and pregnant women, giving Pfizer a broad regional label.

Positioning in the vaccine calendar

Walk into a German GP practice in autumn and you see the familiar flu vaccine boxes and COVID boosters stacked in refrigerators. Pfizer wants Abrysvo to sit alongside them as the RSV pillar in that seasonal respiratory line-up, especially for patients already scheduling their flu shot. Pfizer Germany communicates that RSV can cause serious lower respiratory tract disease in older adults, with symptoms like coughing, wheezing and difficulty breathing similar to flu or COVID but from a different virus. For pregnant women, the pitch is simpler: one shot in late pregnancy to help protect the baby during its first RSV season when hospitals see infant wards filling quickly.

Albert Bourla, CEO of Pfizer, called RSV "one of the remaining major respiratory threats" during the company’s vaccine portfolio presentations and highlighted Abrysvo as a key launch adding to its post-COVID revenue base. In US Advisory Committee on Immunization Practices (ACIP) documents, Abrysvo is listed as one of two RSV vaccines recommended for older adults, alongside GSK’s Arexvy, with detailed guidance that vaccination should be based on shared clinical decision-making between patient and provider rather than a blanket recommendation. That matters for demand forecasting: uptake depends on how strongly physicians recommend RSV vaccination to their at-risk patients.

Clinical data and safety profile

Abrysvo’s approvals rest on the phase 3 RENOIR and MATISSE trials, each with thousands of participants. In the RENOIR study of adults 60+, Abrysvo showed significant efficacy against RSV-related lower respiratory tract disease, with a reduction in medically attended RSV illness compared with placebo. In the MATISSE trial in pregnant women, vaccination during weeks 24 to 36 of gestation led to fewer severe RSV cases in infants during the first six months of life.

As always with vaccines, the detail lies in the safety tables. Common side effects listed by Pfizer include pain at the injection site, fatigue, headache and muscle pain, typically resolving within a few days. Regulatory agencies also flagged rare but serious events, such as Guillain-Barré syndrome in older adults, which are being monitored through post-marketing surveillance. In its EMA public assessment report, the agency concludes that the benefit-risk balance for Abrysvo is positive when used according to the approved indications.

Availability and pricing

For Germany, Abrysvo is available on prescription and is gradually making its way into seasonal vaccination programs, though reimbursement conditions vary from one health insurer to another. The vaccine is distributed through standard pharmaceutical wholesalers that deliver to community practices and clinics, with cold-chain handling requirements similar to other protein-based vaccines. In practice, that means Abrysvo boxes leave Pfizer’s logistics centers in temperature-controlled vans and end up in those humming medical fridges behind reception desks, between the flu vials and tetanus boosters.

Pfizer does not publish a single global list price for Abrysvo, and pricing is negotiated market by market. In the US, analysts tracking wholesale acquisition costs report list prices in the range typical for other adult vaccines, often cited around a few hundred dollars per dose before rebates, though actual prices paid by health plans are lower. In Europe, national health systems and private insurers negotiate confidential discounts, so end-user pricing is mostly visible through reimbursement decisions rather than price tags in pharmacies.

Strategic role in Pfizer’s portfolio

In corporate presentations, Abrysvo sits in Pfizer’s "Vaccines" segment alongside its pneumococcal and meningococcal shots as well as COVID booster candidates. The RSV category is new, and Pfizer’s strategy is clear: become one of the main suppliers for older adults and maternal RSV vaccination in major markets, positioning Abrysvo as a long-term contributor rather than a one-off pandemic product. Bourla has emphasized that respiratory vaccines, including RSV, are central to stabilizing revenues after the COVID vaccine boom.

Analysts see the RSV market as a multi-billion-dollar opportunity once awareness builds among physicians and patients. For holders of Pfizer Inc. stock, vaccines like Abrysvo matter because they tap into an aging global population and renewed focus on infectious disease prevention. On the Xetra trading venue in Frankfurt, Pfizer Inc. is available via an exchange listing in euros, and investors are watching how RSV vaccine uptake translates into medium-term sales numbers.